LeMaitre Vascular (LMAT) Competitors

LeMaitre Vascular (NASDAQ:LMAT) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, community ranking, dividends, valuation and earnings.

Does the MarketBeat Community prefer LMAT or MDXG?

LeMaitre Vascular received 468 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 81.82% of users gave MiMedx Group an outperform vote while only 70.86% of users gave LeMaitre Vascular an outperform vote.

Company	Underperform	Outperform
LeMaitre Vascular	Outperform Votes 513 70.86%	Underperform Votes 211 29.14%
MiMedx Group	Outperform Votes 45 81.82%	Underperform Votes 10 18.18%

Is LMAT or MDXG more profitable?

MiMedx Group has a net margin of 23.86% compared to LeMaitre Vascular's net margin of 19.40%. MiMedx Group's return on equity of 26.21% beat LeMaitre Vascular's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	19.40%	13.15%	11.47%
MiMedx Group	23.86%	26.21%	18.15%

Do institutionals & insiders have more ownership in LMAT or MDXG?

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 10.8% of LeMaitre Vascular shares are owned by insiders. Comparatively, 1.3% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts prefer LMAT or MDXG?

LeMaitre Vascular presently has a consensus target price of $94.57, suggesting a potential downside of 7.30%. MiMedx Group has a consensus target price of $12.00, suggesting a potential upside of 29.31%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to LMAT or MDXG?

In the previous week, MiMedx Group had 7 more articles in the media than LeMaitre Vascular. MarketBeat recorded 10 mentions for MiMedx Group and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.16 beat MiMedx Group's score of 0.64 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation and earnings, LMAT or MDXG?

MiMedx Group has higher revenue and earnings than LeMaitre Vascular. MiMedx Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$193.48M	11.85	$30.10M	$1.83	55.75
MiMedx Group	$321.48M	4.24	$58.23M	$0.55	16.87

Which has more volatility & risk, LMAT or MDXG?

LeMaitre Vascular has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500.

Summary

MiMedx Group beats LeMaitre Vascular on 10 of the 19 factors compared between the two stocks.